Our mission is to deliver solutions and bring hope to as many people as possible.
Biosimilar medicines enable us to do so, by ensuring access to treatments and contributing to the sustainability of healthcare systems worldwide.
More info
mAbNews
ESMO publication: EMA grants a marketing authorisation for two biosimilar medicines, bevacizumab
02/15/2021
They received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix
Spanish group Insud Pharma signs agreement with AstraZeneca to manufacture COVID-19 vaccine candidate
01/20/2021
The plant in Spain’s Castilla-La Mancha region will undertake vial filling and packaging for AZD1222 The company also provides drug substance manufacturing for AZD1222 through their site in Argentina Insud Pharma is at the forefront of Spanish companies in investment in R&D The Spanish pharmaceutical group Insud Pharma will provide vial filling and packaging of […]
mAbxience enters into an agreement with AstraZeneca to produce Covid-19 vaccine
08/17/2020
mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico to complete the production and […]
